JP2005523263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523263A5 JP2005523263A5 JP2003563565A JP2003563565A JP2005523263A5 JP 2005523263 A5 JP2005523263 A5 JP 2005523263A5 JP 2003563565 A JP2003563565 A JP 2003563565A JP 2003563565 A JP2003563565 A JP 2003563565A JP 2005523263 A5 JP2005523263 A5 JP 2005523263A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- fibrosis
- composition according
- scarring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000037390 scarring Effects 0.000 claims 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202254.9A GB0202254D0 (en) | 2002-01-31 | 2002-01-31 | Prevention of scarring |
| PCT/IB2003/000134 WO2003063875A1 (en) | 2002-01-31 | 2003-01-21 | Use of pde5 inhibitors in the treatment of scarring and fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523263A JP2005523263A (ja) | 2005-08-04 |
| JP2005523263A5 true JP2005523263A5 (enExample) | 2005-12-22 |
Family
ID=9930135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003563565A Pending JP2005523263A (ja) | 2002-01-31 | 2003-01-21 | 瘢痕化及び繊維症の治療におけるｐｄｅ５阻害剤の使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1469857A1 (enExample) |
| JP (1) | JP2005523263A (enExample) |
| BR (1) | BR0307410A (enExample) |
| CA (1) | CA2474852A1 (enExample) |
| GB (1) | GB0202254D0 (enExample) |
| MX (1) | MXPA04007430A (enExample) |
| TW (1) | TW200302105A (enExample) |
| WO (1) | WO2003063875A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0410326A (pt) * | 2003-05-22 | 2006-05-23 | Altana Pharma Ag | composição compreendendo um inibidor pde4 e inibidor pde5 |
| AU2005277384B2 (en) | 2004-08-17 | 2011-11-17 | The Johns Hopkins University | PDE5 inhibitor compositions and methods for treating cardiac indications |
| CA2619779C (en) * | 2004-08-19 | 2013-03-12 | Switch Biotech Ag | Use of a pde5 inhibitor for treating and preventing hypopigmentary disorders |
| DE602004022463D1 (de) * | 2004-08-19 | 2009-09-17 | Switch Biotech Llc | Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen |
| WO2006074443A2 (en) * | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| US20090215782A1 (en) * | 2005-04-18 | 2009-08-27 | Carlo Foresta | Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease |
| RU2369392C2 (ru) * | 2005-06-10 | 2009-10-10 | Донг-А Фармасьютикал. Ко., Лтд. | Средство для профилактики и лечения заболеваний печени, содержащее производное пиразолопиримидинона |
| AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
| CN102970965A (zh) * | 2010-04-05 | 2013-03-13 | Sk化学公司 | 含有pde5抑制剂的减少皮肤皱纹的合成物 |
| ES2549979T3 (es) * | 2010-05-26 | 2015-11-03 | Adverio Pharma Gmbh | El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS) |
| EP2753332B1 (en) * | 2011-09-09 | 2017-02-15 | SK Chemicals Co., Ltd. | Mridenafil for reducing skin wrinkles |
| AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
| ES2700989T3 (es) | 2012-12-21 | 2019-02-20 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
| CN105380949A (zh) * | 2014-09-02 | 2016-03-09 | 健脂生物科技股份有限公司 | 治疗高脂肪食品诱发肝脏脂肪蓄积的组合物 |
| CA3055882A1 (en) | 2017-03-14 | 2018-09-20 | Atir Holding S.A. | Topical formulation for the treatment of pigmented skin |
| US11033549B2 (en) | 2017-03-14 | 2021-06-15 | Atir Holding S.A. | Use of heterocyclic compounds in the treatment of pigmented skin |
| MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
| SG11202110533RA (en) | 2019-04-10 | 2021-10-28 | Mayo Found Medical Education & Res | Methods and materials for gender-dependent treatment of cardiovascular dysfunction |
| CN112773898A (zh) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用 |
| US20230218622A1 (en) * | 2021-08-13 | 2023-07-13 | Mezzion Pharma Co., Ltd. | Methods and compositions for treating fibrotic liver conditions, using udenafil compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US5965501A (en) * | 1997-03-28 | 1999-10-12 | Lever Brothers Company, Division Of Conopco, Inc. | Personal washing bar compositions comprising emollient rich phase/stripe |
| WO1999026946A1 (en) * | 1997-11-26 | 1999-06-03 | Mochida Pharmaceutical Co., Ltd. | PYRIDOCARBAZOLE DERIVATIVES WITH cGMP-PDE INHIBITORY ACTIVITY |
| ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
| GB9909135D0 (en) * | 1999-04-22 | 1999-06-16 | Univ Wales Medicine | Cystic fibrosis medicaments |
| US6503908B1 (en) * | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
-
2002
- 2002-01-31 GB GBGB0202254.9A patent/GB0202254D0/en not_active Ceased
-
2003
- 2003-01-21 JP JP2003563565A patent/JP2005523263A/ja active Pending
- 2003-01-21 MX MXPA04007430A patent/MXPA04007430A/es unknown
- 2003-01-21 EP EP20030734608 patent/EP1469857A1/en not_active Withdrawn
- 2003-01-21 WO PCT/IB2003/000134 patent/WO2003063875A1/en not_active Ceased
- 2003-01-21 CA CA002474852A patent/CA2474852A1/en not_active Abandoned
- 2003-01-21 BR BR0307410-2A patent/BR0307410A/pt not_active IP Right Cessation
- 2003-01-24 TW TW092101618A patent/TW200302105A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523263A5 (enExample) | ||
| JP2023166406A5 (enExample) | ||
| NO20061254L (no) | Farmasoytiske blandinger | |
| JP2023088944A5 (enExample) | ||
| UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| JP2005515964A5 (enExample) | ||
| WO2007109118A3 (en) | RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS | |
| JP2015057436A5 (enExample) | ||
| JP2006518387A5 (enExample) | ||
| CO5550426A2 (es) | Novedoso metodo terapeutico | |
| JP2006512324A5 (enExample) | ||
| JP2009518415A5 (enExample) | ||
| WO2005011614A8 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease | |
| JP2008523102A5 (enExample) | ||
| RU2007107915A (ru) | Лекарственные средства для лечения хронического респираторного заболевания | |
| JP2005513014A5 (enExample) | ||
| WO2005011594A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease | |
| JP2003508467A5 (enExample) | ||
| JP2005537282A5 (enExample) | ||
| JP2023524693A (ja) | ラクトフェリンの投与によるＳＡＲＳ－ＣｏＶ－２ウイルス侵入の阻害およびその使用 | |
| HUT70054A (en) | Pentofixillin for producing pharmaceutical compositions for treating lung diseases of granuloma and fibrozis | |
| WO2005011608A3 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR | |
| WO2005011604A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease | |
| Yamaura et al. | Recurrent ventricular tachyarrhythmias associated with QT prolongation following hydrofluoric acid burns |